A drug targeting 5‑lipoxygenase enhances the activity of a JAK2 inhibitor in CD34<sup>+</sup> bone marrow cells from patients with JAK2V617F‑positive polycythemia vera <em>in vitro</em>

Chen,Yuan; Zhao,Hu; Luo,Jing; Liao,Youping; Tan,Kui; Hu,Guoyu

doi:10.3892/ol.2021.12612

A drug targeting 5‑lipoxygenase enhances the activity of a JAK2 inhibitor in CD34⁺ bone marrow cells from patients with JAK2V617F‑positive polycythemia vera in vitro

Authors:
- Yuan Chen
- Hu Zhao
- Jing Luo
- Youping Liao
- Kui Tan
- Guoyu Hu
View Affiliations

Affiliations: Department of Hematology, The Affiliated Zhuzhou Hospital Xiangya Medical College CSU, Zhuzhou, Hunan 412000, P.R. China
Published online on: March 4, 2021 https://doi.org/10.3892/ol.2021.12612
Article Number: 351
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Janus kinase 2 (JAK2) inhibitors, the first targeted treatments for myeloproliferative neoplasms (MPNs), provide substantial benefits, including a marked reduction in splenomegaly and MPN‑associated symptoms. However, these drugs rarely induce molecular remission in patients with MPNs. Zileuton, a 5‑lipoxygenase (5‑LO) inhibitor, has been demonstrated to selectively deplete hematopoietic stem cells (HSCs) expressing a JAK2 point mutation (JAK2V617F) in mouse models of JAK2V617F‑induced polycythemia vera (PV). To determine the potential activity of 5‑LO inhibitors in combination with JAK inhibitors against human PV HSCs, the present study first analyzed 5‑LO expression in CD34⁺ bone marrow cells from patients with JAK2V617F‑positive PV using western blotting and reverse transcription‑quantitative PCR, and then examined the effect of zileuton combined with ruxolitinib on colony formation using a colony formation assay. Furthermore, cell cycle and apoptosis in CD34⁺ cells from patients with PV and healthy volunteers were determined by ﬂow cytometry. In the present study, 5‑LO expression was upregulated in CD34⁺ cells from patients with PV compared with in CD34⁺ cells from healthy volunteers. Higher levels of leukotriene B4, a product of the 5‑LO signaling pathway, were detected in patients with PV compared with in healthy volunteers. Zileuton treatment suppressed the colony formation of CD34⁺ cells from patients with PV in a dose‑dependent manner. Furthermore, zileuton and ruxolitinib exerted their anticancer effects by suppressing hematopoietic colony formation, inducing apoptosis and arresting the cell cycle of human CD34⁺ cells from patients with PV. The combination of these two drugs exerted a more beneficial effect than either agent alone. Based on these data, zileuton enhanced the antitumor activity of low‑dose ruxolitinib in hematopoietic progenitor cells from patients with PV, providing conceptual validation for further clinical applications of combination treatment with ruxolitinib and zileuton for patients with PV.

View Figures

View References

1	Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405. 2016. View Article : Google Scholar : PubMed/NCBI
2	Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, et al: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 365:1054–1061. 2005. View Article : Google Scholar : PubMed/NCBI
3	James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, et al: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 434:1144–1148. 2005. View Article : Google Scholar : PubMed/NCBI
4	Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, et al: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 106:2162–2168. 2005. View Article : Google Scholar : PubMed/NCBI
5	Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M and Skoda RC: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 352:1779–1790. 2005. View Article : Google Scholar : PubMed/NCBI
6	Deininger M, Radich J, Burn TC, Huber R and Verstovsek S: The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood. 126:1551–1554. 2015. View Article : Google Scholar : PubMed/NCBI
7	Cervantes F and Pereira A: Does ruxolitinib prolong the survival of patients with myelofibrosis? Blood. 129:832–837. 2017. View Article : Google Scholar : PubMed/NCBI
8	Needleman P, Turk J, Jakschik BA, Morrison AR and Lefkowith JB: Arachidonic acid metabolism. Ann Rev Biochem. 55:69–102. 1986. View Article : Google Scholar : PubMed/NCBI
9	Peters-Golden M and Henderson WR Jr: Leukotrienes. N Engl J Med. 357:1841–1854. 2007. View Article : Google Scholar : PubMed/NCBI
10	Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O'Byrne K, Nie D and Honn KV: Lipoxygenase metabolism: Roles in tumor progression and survival. Cancer Metastasis Rev. 26:503–524. 2007. View Article : Google Scholar : PubMed/NCBI
11	Wang D and Dubois RN: Eicosanoids and cancer. Nat Rev Cancer. 10:181–193. 2010. View Article : Google Scholar : PubMed/NCBI
12	Bishayee K and Khuda-Bukhsh AR: 5-lipoxygenase antagonist therapy: A new approach towards targeted cancer chemotherapy. Acta Biochim Biophys Sin (Shanghai). 45:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
13	Moore GY and Pidgeon GP: Cross-talk between cancer cells and the tumour microenvironment: The role of the 5-lipoxygenase pathway. Int J Mol Sci. 18:2362017. View Article : Google Scholar
14	Chen Y, Shan Y, Lu M, DeSouza N, Guo Z, Hoffman R, Liang A and Li S: Alox5 blockade eradicates JAK2V617F-induced polycythemia Vera in mice. Cancer Res. 77:164–174. 2017. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Mehta J, Wang H, Iqbal SU and Mesa R: Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 55:595–600. 2014. View Article : Google Scholar : PubMed/NCBI
17	Hoffman R, Prchal JT, Samuelson S, Ciurea SO and Rondelli D: Philadelphia chromosome-negative myeloproliferative disorders: Biology and treatment. Biol Blood Marrow Transplant. 13 (Suppl 1):S64–S72. 2007. View Article : Google Scholar
18	Mascarenhas J: A concise update on risk factors, therapy, and outcome of leukemic transformation of myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk. 16 (Suppl):S124–S129. 2016. View Article : Google Scholar : PubMed/NCBI
19	Silvennoinen O and Hubbard SR: Molecular insights into regulation of JAK2 in myeloproliferative neoplasms. Blood. 125:3388–3392. 2015. View Article : Google Scholar : PubMed/NCBI
20	Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia Vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 7:387–397. 2005. View Article : Google Scholar : PubMed/NCBI
21	Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, et al: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 366:799–807. 2012. View Article : Google Scholar : PubMed/NCBI
22	Hasselbalch HC and Bjørn ME: Ruxolitinib versus standard therapy for the treatment of polycythemia Vera. N Engl J Med. 372:16702015. View Article : Google Scholar : PubMed/NCBI
23	Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, et al: Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. JAMA Oncol. 1:643–651. 2015. View Article : Google Scholar : PubMed/NCBI
24	Kiladjian J, Verstovsek S, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, et al: Results from the 208-week (4-year) Follow-up of RESPONSE Trial, a Phase 3 study comparing ruxolitinib (Rux) with best available therapy (BAT) for the treatment of polycythemia Vera (PV). Blood. 130 (Suppl 1):S3222017.
25	Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, Harrison CN, Paquette R, Sun W, Naim A, et al: Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 10:1562017. View Article : Google Scholar : PubMed/NCBI
26	Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, et al: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs. best available therapy for myelofibrosis. Leukemia. 31:7752016. View Article : Google Scholar
27	Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, et al: Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 10:552017. View Article : Google Scholar : PubMed/NCBI
28	Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, et al: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 366:787–798. 2012. View Article : Google Scholar : PubMed/NCBI
29	Avis I, Hong SH, Martínez A, Moody T, Choi YH, Trepel J, Das R, Jett M and Mulshine JL: Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J. 15:2007–2009. 2001. View Article : Google Scholar : PubMed/NCBI
30	Melstrom LG, Bentrem DJ, Salabat MR, Kennedy TJ, Ding XZ, Strouch M, Rao SM, Witt RC, Ternent CA, Talamonti MS, et al: Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res. 14:6525–6530. 2008. View Article : Google Scholar : PubMed/NCBI
31	Hennig R, Ding XZ, Tong WG, Schneider MB, Standop J, Friess H, Büchler MW, Pour PM and Adrian TE: 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol. 161:421–428. 2002. View Article : Google Scholar : PubMed/NCBI
32	Hoque A, Lippman SM, Wu TT, Xu Y, Liang ZD, Swisher S, Zhang H, Cao L, Ajani JA and Xu XC: Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: A potential target for prevention. Carcinogenesis. 26:785–791. 2005. View Article : Google Scholar : PubMed/NCBI
33	Matsuyama M, Yoshimura R, Mitsuhashi M, Hase T, Tsuchida K, Takemoto Y, Kawahito Y, Sano H and Nakatani T: Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int J Oncol. 24:821–827. 2004.PubMed/NCBI
34	Hyde CA and Missailidis S: Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. Int Immunopharmacol. 9:701–715. 2009. View Article : Google Scholar : PubMed/NCBI
35	Ding XZ, Iversen P, Cluck MW, Knezetic JA and Adrian TE: Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun. 261:218–223. 1999. View Article : Google Scholar : PubMed/NCBI
36	Wen Z, Liu H, Li M, Li B, Gao W, Shao Q, Fan B, Zhao F, Wang Q, Xie Q, et al: Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration. Oncogene. 34:1241–1252. 2015. View Article : Google Scholar : PubMed/NCBI
37	Hassan S and Carraway RE: Involvement of arachidonic acid metabolism and EGF receptor in neurotensin-induced prostate cancer PC3 cell growth. Regul Pept. 133:105–114. 2006. View Article : Google Scholar : PubMed/NCBI
38	Karlage KL, Mogalian E, Jensen A and Myrdal PB: Inhalation of an ethanol-based zileuton formulation provides a reduction of pulmonary adenomas in the A/J mouse model. AAPS PharmSciTech. 11:168–173. 2010. View Article : Google Scholar : PubMed/NCBI
39	Romano M, Catalano A, Nutini M, D'Urbano E, Crescenzi C, Claria J, Libner R, Davi G and Procopio A: 5-Lipoxygenase regulates malignant mesothelial cell survival: Involvement of vascular endothelial growth factor. FASEB J. 15:2326–2336. 2001. View Article : Google Scholar : PubMed/NCBI
40	Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC and Cho CH: Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis. 26:827–834. 2005. View Article : Google Scholar : PubMed/NCBI
41	Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, et al: Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 139:891–906. 2009. View Article : Google Scholar : PubMed/NCBI
42	Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, Le QT and Giaccia AJ: Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 15:35–44. 2009. View Article : Google Scholar : PubMed/NCBI
43	Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM, Sommer P, Csiszar K and Hendrix MJ: A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res. 62:4478–4483. 2002.PubMed/NCBI
44	Graham SM, Vass JK, Holyoake TL and Graham GJ: Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells. 25:3111–3120. 2007. View Article : Google Scholar : PubMed/NCBI
45	Roos J, Oancea C, Heinssmann M, Khan D, Held H, Kahnt AS, Capelo R, La Buscato E, Proschak E, Puccetti E, et al: 5-Lipoxygenase is a candidate target for therapeutic management of stem cell-like cells in acute myeloid leukemia. Cancer Res. 74:5244–5255. 2014. View Article : Google Scholar : PubMed/NCBI
46	Chen Y, Hu Y, Zhang H, Peng C and Li S: Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet. 41:783–792. 2009. View Article : Google Scholar : PubMed/NCBI
47	Ruiz-Herguido C, Guiu J, D'Altri T, Inglés-Esteve J, Dzierzak E, Espinosa L and Bigas A: Hematopoietic stem cell development requires transient Wnt/β-catenin activity. J Exp Med. 209:1457–1468. 2012. View Article : Google Scholar : PubMed/NCBI
48	Hu Y, Chen Y, Douglas L and Li S: Beta-catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia. 23:109–116. 2009. View Article : Google Scholar : PubMed/NCBI
49	Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A and Reya T: Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 12:528–541. 2007. View Article : Google Scholar : PubMed/NCBI
50	Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, Kalaitzidis D, Lane SW and Armstrong SA: Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell. 10:412–424. 2012. View Article : Google Scholar : PubMed/NCBI
51	Lucas CM, Harris RJ, Giannoudis A, Mcdonald E and Clark RE: Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia. Haematologica. 99:1710–1715. 2014. View Article : Google Scholar : PubMed/NCBI
52	Dolinska M, Piccini A, Wong WM, Gelali E, Johansson AS, Klang J, Xiao P, Yektaei-Karin E, Strömberg UO, Mustjoki S, et al: Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34⁺ CD38⁻ stem and progenitor cells in chronic myeloid leukemia. Biochem Biophys Res Commun. 490:378–384. 2017. View Article : Google Scholar : PubMed/NCBI